Your browser doesn't support javascript.
loading
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho, Jenny N H G; Schmidt, Dominik; Lowinus, Theresa; Ryoo, Jeongmin; Dopfer, Elaine-Pashupati; Gonzalo Núñez, Nicolás; Costa-Pereira, Sara; Toffalori, Cristina; Punta, Marco; Fetsch, Viktor; Wertheimer, Tobias; Rittmann, Marie-Claire; Braun, Lukas M; Follo, Marie; Briere, Christelle; Vinnakota, Janaki Manoja; Langenbach, Marlene; Koppers, Felicitas; Shoumariyeh, Khalid; Engel, Helena; Rückert, Tamina; Märklin, Melanie; Holzmayer, Samuel; Illert, Anna L; Magon, Federica; Andrieux, Geoffroy; Duquesne, Sandra; Pfeifer, Dietmar; Staniek, Julian; Rizzi, Marta; Miething, Cornelius; Köhler, Natalie; Duyster, Justus; Menssen, Hans D; Boerries, Melanie; Buescher, Joerg M; Cabezas-Wallscheid, Nina; Blazar, Bruce R; Apostolova, Petya; Vago, Luca; Pearce, Erika L; Becher, Burkhard; Zeiser, Robert.
Affiliation
  • Ho JNHG; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Schmidt D; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Lowinus T; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Ryoo J; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Dopfer EP; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Gonzalo Núñez N; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Costa-Pereira S; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Toffalori C; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Punta M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Fetsch V; Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.
  • Wertheimer T; Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.
  • Rittmann MC; Center for Omics Sciences, IRCCS San Raffaele Institute, Milano, Italy.
  • Braun LM; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Follo M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Briere C; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Vinnakota JM; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Langenbach M; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Koppers F; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Shoumariyeh K; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Engel H; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Rückert T; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Märklin M; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Holzmayer S; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Illert AL; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Magon F; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Andrieux G; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research, Center (DKFZ), Heidelberg, Germany.
  • Duquesne S; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Pfeifer D; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Staniek J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Rizzi M; Deutsche Forschungsgemeinschaft Cluster of Excellence 2180 "Image-guided and Functional Instructed Tumor Therapy," University of Tuebingen, Tuebingen, Germany.
  • Miething C; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
  • Köhler N; Deutsche Forschungsgemeinschaft Cluster of Excellence 2180 "Image-guided and Functional Instructed Tumor Therapy," University of Tuebingen, Tuebingen, Germany.
  • Duyster J; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Menssen HD; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research, Center (DKFZ), Heidelberg, Germany.
  • Boerries M; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Buescher JM; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research, Center (DKFZ), Heidelberg, Germany.
  • Cabezas-Wallscheid N; Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Blazar BR; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Apostolova P; Clinic of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Vago L; Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
  • Pearce EL; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Centre.
  • Becher B; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Centre.
  • Zeiser R; Signalling Research Centres BIOSS and CIBSS - Centre for Integrative Biological, Signalling Studies, and.
Blood ; 140(10): 1167-1181, 2022 09 08.
Article de En | MEDLINE | ID: mdl-35853161
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Protéine p53 suppresseur de tumeur Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Blood Année: 2022 Type de document: Article Pays d'affiliation: Allemagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Protéine p53 suppresseur de tumeur Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Blood Année: 2022 Type de document: Article Pays d'affiliation: Allemagne